Hungarian Immunology

[EULAR]

SZEKANECZ Zoltán

JANUARY 22, 2008

Hungarian Immunology - 2008;7(01-02)

COMMENTS

0 comments

Further articles in this publication

Hungarian Immunology

[Etanercept in early rheumatoid arthritis]

SZEKANECZ Zoltán

Hungarian Immunology

[Kinetic measurement on flow cytometer simultaneous monitoring of intracellular progresses]

MÉSZÁROS Gergő, RÓNAI Katalin Zsuzsanna, TOLDI Gergely, KAPOSI Ambrus, VÁSÁRHELYI Barna, TRESZL András

[INTRODUCTION - Flow cytometry provides an opportunity for real-time monitoring of intracellular processes in several cell populations simultaneously. Cells stained with specific fluorescent dyes are sequentially measured during kinetic FACS measurements. Fluorescent light signals obtained in cells are recorded and analyzed to describe the alteration of the investigated parameter(s) over time. The use of kinetic FACS assays is not spread as there was no mathematic algorithm to characterize objectively the distribution of data and kinetic changes. MATERIALS, METHODS, RESULTS - We developed a new approach which fits functions to measured data sets, describes the statistical distribution and forms a basis for statistical comparison between individual kinetic measurements. We created two FACS assays on BD FACS Aria instrument. The first one monitors calcium flux, generation of reactive oxygen species and mitochondrial membrane potential, while the second one monitors mitochondrial calcium flux, nitric oxide generation and plasma membrane potential in CD4+ and CD8+ lymphocytes simultaneously before and after the administration of a lymphocyte activator. CONCLUSIONS - This technique may be used to investigate purposes (i.e. to test the impact of any agent (such as immunmodulatory drugs) on cellular processes in lymphocytes) and to diagnostic purposes (i.e. to test the alteration of lymphocyte activation characteristics in disease).]

Hungarian Immunology

[Pseudolymphoma orbitae]

VÁNCSA Andrea, GERGELY Lajos, NEMES Zoltán, BÍRÓ Edit, ILLÉS Árpád, BAKÓ Gyula

[INTRODUCTION - Pseudolymphoma orbitae is a rare and difficult entity. The cooperation of the pathologist and clinician is needed to properly manage the patient. CASE REPORT - The authors report the case history of a 38 years old male patient. His disease started at the age of 30. He was previously treated with allergic rhinitis. No definitive diagnosis was made for eight years. Several surgical biopsies were made from nasal mucosa, but no specific histologyical diagnosis was applicable. At the age of 30 he developed an unilateral exophthalmus on the left side. Thyroid associated ophthalmopathy was ruled out several times with laboratory analysis. High dose methylprednisone therapy was repeatedly given with limited results. At the age of 34 orbital CT and MRI scan confirmed the pseudotumour orbitae already compressing the optical nerve. Laboratory analysis again ruled out thyroid associated ophthalmopathy. Churg-Strauss syndrome, Wegener’s granulomatosis or Sjögren’s syndrome could be ruled out. A bone marrow trephine biopsy excluded systemic hematological disease as well. A biopsy was performed from the retrobulbar mass again, which confirmed the lymphoid hyperplasia with B-cell dominance. High dose methylprednisone and local irradiation resulted only moderate decrease of the mass, so systemic chemotherapy was started using CVP (cyclophosphamide, vincristin, prednisone) then CHOP (CVP + anthrycycline) polychemotherapy for eight cycles and subcutaneous interferon-α for 20 months. CONCLUSIONS - This resulted a complete regression of the disease, and the patient is well for 48 months now.]

Hungarian Immunology

[Comparison of disease-modifying drugs in rheumatoid arthritis]

SZŰCS Gabriella, SZEKANECZ Zoltán

Hungarian Immunology

[Etoricoxib in the treatment of rheumatoid arthritis]

MATSUMOTO AK, MELIAN A, MANDEL DR

All articles in the issue

Related contents

Hungarian Immunology

[6th Congress of EULAR]

SZEKANECZ Zoltán

Hypertension and nephrology

[Novelties in the treatment of hyperuricemia and gout: treat to target principle in focus]

ALFÖLDI Sándor

[The prevalence of hyperuricemia is is increasing as it is related by several different mechanisms to obesity and metabolic syndrome spreading epidemically worldwide. Several beneficial cardiovascular and renorotective effects of the xanthin-oxydase inhibitor allopurinol, administered in the treatment of hyperuricemia and gout, have been found out recently. The newest European EULAR guidelines for the treatment of gout recommended the treat-to target principle. A target value of ≤360 umol/l in patients with mild-to moderate gout and ≤300 umol/l in more serious cases has been suggested. The guidelines took an unequivocal commitment, that allopurinol is the first-line treatment. The hypouricemic therapy should be started as soon as possible after the diagnosis and should be continued lifelong in patients with gout.]

Lege Artis Medicinae

[Updated EULAR recommendations for the management of hand osteoarthritis]

HODINKA László

Hungarian Immunology

[EULAR 2007]

SZEKANECZ Zoltán

Hungarian Immunology

[EULAR and ACR Conference, 02003.]

SZEKANECZ Zoltán